USA-based Medivation (NASDAQ: MDVN) and global drugs behemoth Pfizer (NYSE: PFE) have finally decided to discontinue the development of Dimebon also known as latrepirdine, for all indications and will terminate the ongoing open label extension study in Alzheimer’s disease.
Leading Pharma industry experts plan to be at the Pharma Market Research Conference which takes place on February 7-8 at the Hilton Parsippany Hotel in New Jersey.
Antares Pharma has recently announced that it has licensed to Pfizer Inc.’s Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America. The companies did not disclose specifics of the deal.
Humana, one of the nation's largest health care companies, and Pfizer, the world's largest biopharmaceutical company, have recently linked together to explore new ideas and ways to improve the quality, outcomes and costs of the health care delivery system for senior citizens and other population.
Recently, US Food and Drug Administration (FDA) has advised health providers not to use needle free injector devices to administer influenza vaccines, because so far no flu vaccines have been approved for administration using such devices, saying they are approved for only the measles, mumps and rubella vaccine.
Structure / Market Size The US Sector $ 12 billion valued pharmaceutical industry in India is expected to grow at an compound annual growth rate (CAGR) of 10-11 per cent. The industry spends around 18 per cent of its revenue on research and development (R&D).
Air fresheners which are used for clean refreshing house or car may smells sweet but very few people understand how bad air fresheners are for their health. Science has confirmed that though air freshener smells sweet but they may cause lung cancer. People with asthma or allergies may want to avoid air fresheners and other chemicals used to spread fragrant scents through their homes, and their doctors should be aware of the hazards.
A highly organized sector, the Indian pharmaceutical industry is estimated to be worth $4.5 billion, growing at about 8% to 9% every year.
Ahmedabad based Contract Research and Manufacturing Services (CRAMS) major Dishman Pharmaceuticals and Chemicals Ltd has entered into a strategic alliance with California based biotechnology firm Codexis, Inc. that will allow Dishman to use of Codexis' proprietary enzymatic biocatalysis technology to manufacture intermediates and active pharmaceutical intermediates (APIs).
The Indian drug industry could make huge gains as over $70 billion worth of drugs are expected to go off patent in the US, the world’s largest pharma market, in the next three years.
If a shareholder had invested about Rs 2,500 in Dr Reddy's Laboratories through the IPO in August 1986 and the rights issue of 1989, what do you think the holding would be worth today? A whopping Rs 40 lakh!
Sales growth and control on costs helped improve margins.Improved sales across its four business units helped GlaxoSmithKline Pharmaceuticals record an 18 per cent year-on-year growth in gross sales to Rs 453 crore for the December 2009 quarter. This, coupled with lower excise outgo, helped the company post a better-than-expected 20 per cent year-on-year jump in net sales.
Scientists may have finally found a way to deal with one of developing world's worst problems in healthcare — faulty and inadequate cold chain for vaccine storage. British scientists from Oxford University have found a way to keep vaccines stable even in room temperature.
Russia today invited Indian pharmaceutical companies to set up joint ventures in the country.
HarNeedi.com, India’s No. 1 job portal for Healthcare and Pharma industry, will be organizing an exclusive ‘Healthi Job Fair 2010’ for Healthcare and Pharma 'Healthi Job Fair 2010' at the Bombay Exhibition Center, Western Express Highway, Goregaon East, Mumbai on March 20 and 21, 2010.
3SBio Inc, a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Corporation, Ltd have formed a strategic alliance to research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis.
Surging growth and global operations ensure they can’t be family-run any longer.
Like pharma giants Pfizer, Eli Lilly and Merck & Co, US biotechnology major Biogen Idec also doesn’t want to miss the India opportunity.
Avesthagen’s systems biology approach to novel products targets more than land based organisms – dives deep into new products from the OceanAvesthagen has always been in the forefront of innovative scientific thinking and has developed a formidable portfolio of patents in all the four areas it operates in viz. bioAgriculture, bioNutrition, bioPharmacueticals and in Science & Innovation. Approximately 600 patent applications cover both, process and products. There are several copyrights and design patents as well. Within each area Avesthagen aspires to benefit the common man, and more so for the “bottom of the pyramid”.
After witnessing a neutral budget last year, the Indian pharmaceutical industry has prepared itself again with its wish list for Budget 2010.